Content provided by Deborah Roberts. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Deborah Roberts or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
1.12 - Lars Wilde: Scaling The Model For Psilocybin-Assisted Psychotherapy
MP3•Episode home
Manage episode 297721852 series 2896878
Content provided by Deborah Roberts. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Deborah Roberts or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Lars Wilde is the President, Chief Business Officer, and Co-founder of COMPASS Pathways.
COMPASS is a UK life sciences company that works to expedite the approval and delivery of mental health therapies to patients and focuses primarily on testing psilocybin for use in patients with treatment-resistant depression (TRD). They have 22 trials running through the US and Europe for TRD.
In this episode:
- Personal journey and battles with anxiety, and seeking psychiatric help
- The subjective experience of psilocybin and impact of emotional processing and cognitive function
- Birth of COMPASS
- The current landscape of the research
- Models for therapies and how they can scale
- Research questions that need to be addressed
- COMPASS decision to patent psilocybin (and what this means for its scientific exploration)
- Rescheduling psilocybin
Links:
Support the podcast:
Support the mission:
Donate to Mind Medicine Australia
Support this show http://supporter.acast.com/mind-medicine-australia.
Become a member at https://plus.acast.com/s/mind-medicine-australia.
Hosted on Acast. See acast.com/privacy for more information.
53 episodes
MP3•Episode home
Manage episode 297721852 series 2896878
Content provided by Deborah Roberts. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Deborah Roberts or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Lars Wilde is the President, Chief Business Officer, and Co-founder of COMPASS Pathways.
COMPASS is a UK life sciences company that works to expedite the approval and delivery of mental health therapies to patients and focuses primarily on testing psilocybin for use in patients with treatment-resistant depression (TRD). They have 22 trials running through the US and Europe for TRD.
In this episode:
- Personal journey and battles with anxiety, and seeking psychiatric help
- The subjective experience of psilocybin and impact of emotional processing and cognitive function
- Birth of COMPASS
- The current landscape of the research
- Models for therapies and how they can scale
- Research questions that need to be addressed
- COMPASS decision to patent psilocybin (and what this means for its scientific exploration)
- Rescheduling psilocybin
Links:
Support the podcast:
Support the mission:
Donate to Mind Medicine Australia
Support this show http://supporter.acast.com/mind-medicine-australia.
Become a member at https://plus.acast.com/s/mind-medicine-australia.
Hosted on Acast. See acast.com/privacy for more information.
53 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.